Department of Cardiology, Oxford Heart Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK.
BMJ. 2010 Nov 1;341:c5707. doi: 10.1136/bmj.c5707.
To systematically assess the type of outcomes selected and the prevalence of patient reported outcomes in contemporary cardiovascular trials and to quantify any misuse or underuse of patient reported outcomes using a specially developed tool that would allow estimation of the relevance of such outcomes to clinical decision making.
Systematic review.
Medline and Embase.
Randomised controlled trials of the treatment for or prevention of cardiovascular disease published in 10 leading general medical and cardiology journals from January 2005 to December 2008.
Primary outcomes were patient important (death, morbidity, or patient reported outcomes) in only 93 of 413 trials (23%, SE 2%), whereas another 92 (22%, SE 2%) combined these outcomes with other less important ones into a composite. Sixty five trials (16%; SE 2%) used at least one instrument to measure patient reported outcomes, mostly in trials where such information would have been important or crucial for clinical decision making (52 trials). Patient reported outcomes were judged to be of little incremental value to a large number of, mostly explanatory, cardiovascular trials (152 trials). However, many trials in which patient reported outcomes would have been important or crucial for clinical decision making did not report such outcomes (122 of 174 trials, 70%). These included several trials that primarily aimed to improve symptoms or functional status, trials that tested interventions with a considerable potential for causing harm (mainly bleeding) that were not meaningfully measured, and trials with composite outcomes that were dominated by outcomes of questionable importance to patients.
Despite a continued rise in the reporting of patient reported outcomes with no evidence for their misuse in more recent cardiovascular trials, they seem to be still underused once their relevance to clinical decision making has been taken into account. This was largely explained by inappropriate use of composite outcomes and inadequate measurement of harms.
系统评估当代心血管试验中选择的结局类型和患者报告结局的流行程度,并使用专门开发的工具量化患者报告结局的任何误用或使用不足的情况,该工具可用于估计此类结局与临床决策的相关性。
系统评价。
Medline 和 Embase。
2005 年 1 月至 2008 年 12 月,10 种主要的普通医学和心脏病学杂志上发表的心血管疾病治疗或预防的随机对照试验。
仅在 413 项试验中的 93 项(23%,SE 2%)中,主要结局是患者重要的(死亡、发病率或患者报告结局),而另外 92 项(22%,SE 2%)将这些结局与其他不太重要的结局组合成一个综合结局。65 项试验(16%,SE 2%)使用至少一种仪器来测量患者报告的结局,这些试验主要是在这些信息对临床决策有重要或关键意义的情况下进行的(52 项试验)。患者报告的结局被认为对大量主要是解释性的心血管试验没有额外的增量价值(152 项试验)。然而,许多对临床决策有重要或关键意义的患者报告结局的试验并未报告这些结局(174 项试验中的 122 项,70%)。这些试验包括一些主要旨在改善症状或功能状态的试验、测试干预措施的试验,这些干预措施有相当大的潜在危害(主要是出血),而且没有得到有意义的测量,以及主要由对患者重要性有疑问的结局主导的复合结局的试验。
尽管最近的心血管试验中患者报告结局的报告持续增加,且没有证据表明它们的使用存在误用,但一旦考虑到它们与临床决策的相关性,它们似乎仍未得到充分利用。这在很大程度上是由于复合结局的不当使用和危害测量不足。